Get started
Author

Anke Schlenska‐Lange

Observed names: A. Schlenska-Lange, A. Schleska-Lange, A., Schlenska-Lange, Anke Schlenska-Lange, Schlenska-Lange, A., Schlenska-Lange, Anke
Observed institutions: German Cancer Research Center, University Hospital Heidelberg, Krankenhaus Barmherzige Brüder, Hospital of the Brothers of St. John of God, University of Regensburg, Leipzig University
OpenAlex ID: A5003815280
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
2015 · Claus Rödel, Ullrich Graeven, et al. · The Lancet Oncology · 736
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
2012 · Claus Rödel, Torsten Liersch, et al. · The Lancet Oncology · 698
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
2019 · Emmanouil Fokas, Michael Allgäuer, et al. · Journal of Clinical Oncology · 549
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
2021 · Emmanouil Fokas, Anke Schlenska-Lange, et al. · JAMA Oncology · 377
Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells
2021 · Sarah M. Hücker, Tobias Fehlmann, et al. · Nature Communications · 91
PDF
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
2020 · Martin Faehling, Christian Schumann, et al. · Lung Cancer · 80
Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro.
2008 · Anke Schlenska-Lange, Heike Knüpfer, et al. · PubMed · 59
Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer
2020 · Monika Klinkhammer-Schalke, Brunhilde Steinger, et al. · European Journal of Cancer · 46
Community-driven development of a modified progression-free survival ratio for precision oncology
2019 · Andreas Mock, Christoph E Heilig, et al. · ESMO Open · 45
PDF
Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited
2022 · Markus Diefenhardt, Anke Schlenska-Lange, et al. · Cancers · 13
PDF
Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials
2022 · Markus Diefenhardt, Maximillian Fleischmann, et al. · Radiotherapy and Oncology · 11
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
2023 · Benedikt Westphalen, Tobias Gaska, et al. · Journal of Clinical Oncology · 8
Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial
2025 · Jochen Gaedcke, Malte Sahrhage, et al. · Scientific Reports · 5
CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism
2025 · Marianne Sinn, Anja Lohneis, et al. · Oncology Research and Treatment · 4
PDF
Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry
2024 · Nadine Kutsch, Adam Giza, et al. · European Journal Of Haematology · 4
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
2020 · Martin Faehling, Christian Schumann, et al. · Data in Brief · 3
PDF
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients
2024 · Nataša Stojanović Gužvić, Florian Lüke, et al. · Molecular Oncology · 2
1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP)
2020 · M. Faehling, C. Schumann, et al. · Annals of Oncology · 2
PDF
2221P Final results of FOOTPATH: A randomized, open-label phase-II study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC)
2025 · C.B. Westphalen, T. Gaska, et al. · Annals of Oncology · 1
PDF
1440TiP Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III “PREVENT” trial of the AIO/CAOGI/ACO
2021 · U.S. Bankstahl, S-E. Al-Batran, et al. · Annals of Oncology · 1
PDF
Neoadjuvante Regimes im Vergleich
2011 · Anke Schlenska-Lange · Info Onkologie · 1
Organ Preservation and Quality of Life After Total Neoadjuvant Treatment in Rectal Cancer
2026 · Markus Diefenhardt, Emmanouil Fokas, et al. · JAMA Network Open
Reassessing the role of CEA in the treatment of rectal cancer in the era of TNT
2026 · M. Diefenhardt, R.-D. Hofheinz, et al. · ESMO Gastrointestinal Oncology
PDF
Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma: The phase ll IKF-090/AIO ZANGEA trial with translational analysis.
2026 · Joseph Tintelnot, Eray Goekkurt, et al. · Journal of Clinical Oncology
Author response for "Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients"
2024 · Nataša Stojanović Gužvić, Florian Lüke, et al. · Publons reviews and discussion
Works count: 30
Citation count: 2,736
H-index: 11
I10-index: 11
Year
Topic
Type